Partial acute transverse myelitis is a predictor of multiple sclerosis in children

P Meyer1, N Leboucq2, N Molinari3

  • 1CHRU Montpellier, Neuropédiatrie, France INSERM U1046, Université Montpellier 1, Université Montpellier 2, France p-meyer@chu-montpellier.fr.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|March 13, 2014
PubMed

Insights

Acute partial transverse myelitis and brain MRI findings in children predict a later diagnosis of multiple sclerosis. This suggests closer MRI monitoring may enable earlier treatment for pediatric MS.

Area of Science:

  • Pediatric Neurology
  • Neuroimmunology
  • Clinical Research

Background:

  • Acute transverse myelitis (ATM) is a rare, severe pediatric neurological condition.
  • Prognostic factors for ATM, especially the risk of developing multiple sclerosis (MS), are poorly understood in children.

Purpose of the Study:

  • To identify clinical course and prognostic factors following a first episode of ATM in pediatric patients.
  • To investigate predictors for the subsequent diagnosis of MS after pediatric ATM.

Main Methods:

  • Retrospective analysis of 30 children under 16 with a first neurological episode of ATM.
  • Collection of clinical, treatment, laboratory, and MRI data for all participants.

Main Results:

  • 17% of patients were subsequently diagnosed with MS.
  • Acute partial transverse myelitis (OR 5) and brain MRI abnormalities at presentation predicted MS.
  • The 2011 Verhey criteria demonstrated high specificity (96%) and sensitivity (80%) for MS diagnosis in this cohort.

Conclusions:

  • Initial presentation of acute partial transverse myelitis and brain MRI abnormalities are significant predictors of future MS diagnosis in children.
  • Enhanced brain MRI surveillance following ATM may facilitate earlier initiation of disease-modifying therapies for pediatric MS.
Abstract

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53